If upheld on appeal, a federal district judge's ruling Monday that invalidated patent claims related to the BRCA1 and BRCA2 genes held by Salt Lake City-based Myriad Genetics Inc. and the University of Utah Research Foundation could have far-reaching implications for gene patenting and the future of biotechnology product development. (BioWorld Today) Read More
